[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100410808":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":44,"collaborators":19,"id":47,"slug":19,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":19,"eligibilityCriteria":51,"healthyVolunteers":48,"sex":52,"minAge":53,"maxAge":19,"enrollmentInfo":54,"targetDuration":19,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":19,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Imaging cohort","EXPERIMENTAL","All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-WL12 PET\u002FCT scans",[13],"Other: 68Ga-WL12 PET\u002FCT",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"68Ga-WL12 PET\u002FCT","WL12, labeled with PET radio-nuclide ( Ga-68 )will be used as a molecular imaging tracer for PET\u002FCT scanning",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Hua Zhu","CONTACT","010-88196495","zhuhuabch@pku.edu.cn",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Beijing Cancer Hospital","RECRUITING","Beijing","Beijing Municipality","100142","China",{"type":35,"coordinates":36},"Point",[37,38],116.39723,39.9075,{"lat":38,"lon":37},[41],{"name":22,"role":23,"phone":42,"phoneExt":19,"email":43},"+861088196495","zhuhuananjing@163.com",{"type":45,"investigatorFullName":22,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Associate Professor","100410808",false,"NCT04629326","PD-L1 Targeting Molecular Imaging of Solid Tumors","Inclusion Criteria:\n\n* 1\\. Aged \\>18 years old; ECOG 0 or 1;\n* 2\\. Patients with Gastrointestinal tumors;\n* 3\\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1);\n* 4\\. life expectancy \\>=12 weeks.\n\nExclusion Criteria:\n\n* 1\\. Significant hepatic or renal dysfunction;\n* 2\\. Is pregnant or ready to pregnant;\n* 3\\. Cannot keep their states for half an hour;\n* 4\\. Refusal to join the clinical study;\n* 5\\. Suffering from claustrophobia or other mental diseases;\n* 6\\. Any other situation that researchers think it is not suitable to participate in the experiment.","ALL","18 Years",{"count":55,"type":56},20,"ESTIMATED","INTERVENTIONAL",[59],"NA","The objective of the study is to constrcut a noninvasive approach WL12 PET\u002FCT to detect the PD-L1 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from anti-PD-1\u002FL1 treatment.",[62],"Gastrointestinal Tumors","2024-08-16",{"date":65,"type":66},"2024-08-19","ACTUAL",{"date":68,"type":66},"2021-07-20",{"date":70,"type":56},"2024-11",{"name":5,"class":6},1]